Press release
Pegfilgrastim Biosimilars Market Report- Industry Analysis, Growth, Size, Trends Forecast To 2030
Pegfilgrastim Biosimilars Market
Place a DIRECT PURCHASE ORDER of the report @
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3428
The global pegfilgrastim biosimilars market reached a value of nearly $902.1 million in 2020. The pegfilgrastim biosimilars market is expected to grow from $902.1 million in 2020 to $1,801.0 million in 2025 at a rate of 14.8%. The growth in the pegfilgrastim biosimilars market is mainly due to an increased prevalence of cancer and increasing adoption of the biosimilars. The pegfilgrastim biosimilars market is then expected to grow at a CAGR of 17.5% from 2025 and reach $4,037.1 million in 2030.
The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that use them for the treatment of febrile neutropenia – a life-threatening complication of cancer chemotherapy and to increase the production of infection-fighting white blood cells following transplantation. It is a recombinant human granulocyte colony stimulating factor (G-CSF) and helps to stimulate the production of infection-fighting white blood cells (neutrophils) for the treatment of cancer patients undergoing chemotherapy. The drug has further applications where protection from infections where immune system is compromised, such as in bone marrow transplants.
Pegfilgrastim Biosimilars Market Segmentation:
By Application: Chemotherapy Induced Neutropenia, Transplantation
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies
Some of the key players involved in the pegfilgrastim biosimilars market are Coherus BioSciences, Sandoz (Novartis), Biocon/Mylan, Intas Biopharmaceuticals Ltd, Mundipharma GmbH
The regions covered in the global pegfilgrastim biosimilars market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Complete Report @
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market
A Few Points From The Table Of Content
1. Pegfilgrastim Biosimilars Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
……
20. Global Pegfilgrastim Biosimilars Market Competitive Landscape
21. Pegfilgrastim Biosimilars Market Pipeline Analysis
22. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market
23. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis
24. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany/
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Check out our Blog: http://blog.tbrc.info/
Check out our Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Interested to know more about The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. Located globally, it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
The World’s Most Comprehensive Database
The Business Research Company’s flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pegfilgrastim Biosimilars Market Report- Industry Analysis, Growth, Size, Trends Forecast To 2030 here
News-ID: 2528245 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Pegfilgrastim
Pegfilgrastim Biosimilars Market to Reach USD 1.22M by 2035
Can Pegfilgrastim Biosimilars Redefine Supportive Cancer Care Worldwide?
Pegfilgrastim Biosimilars Market: Global Overview, Trends, and Future Outlook
The Pegfilgrastim Biosimilars Market is emerging as a critical component of modern oncology care, driven by the rising global burden of cancer-particularly leukaemia-and the need to reduce the cost of biologic therapies. Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), plays a vital role in preventing chemotherapy-induced neutropenia, a potentially life-threatening complication that increases infection risk…
Global Neulasta (Pegfilgrastim) And Biosimilar Market Size by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Neulasta (Pegfilgrastim) And Biosimilar market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The market for pegfilgrastim and biosimilars is expanding significantly, mostly due to the rising use of chemotherapy-based cancer treatments. By promoting the formation…
Global Pegfilgrastim Market Expects 5.8% Growth Rate from 2021-2028 Amid Rising …
According to the latest report published by Dataintelo, the Global Pegfilgrastim Market is projected to expand at a compound annual growth rate (𝐂𝐀𝐆𝐑) of 5.8% during the period between 2021 and 2028. This significant expansion in the market is primarily driven by the escalating number of cancer cases worldwide and an intensified demand for pegfilgrastim biosimilars.
The report highlights that the evolving global scenario of cancer management and treatment is fostering…
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia.
Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market
Neutropenia patients are highly…
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts.
Pegfilgrastim is a PEGylated…
Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by…
